CRISPR Therapeutics AGCRSPNASDAQ
Loading
Year-over-year free cash flow growth rate
Latest
-9.87%
↑ 91% vs avg
Percentile
P49
Within normal range
Streak
1 qtr
Consecutive declineDecelerating
Average
-106.76%
Historical baseline
| Period | Value |
|---|---|
| Q4 2025 | -9.87% |
| Q3 2025 | 25.69% |
| Q2 2025 | -110.51% |
| Q1 2025 | -7.69% |
| Q4 2024 | 53.06% |
| Q3 2024 | -11.26% |
| Q2 2024 | -188.31% |
| Q1 2024 | 212.62% |
| Q4 2023 | -130.65% |
| Q3 2023 | 69.32% |
| Q2 2023 | -2483.28% |
| Q1 2023 | 104.80% |
| Q4 2022 | -7.45% |
| Q3 2022 | 26.62% |
| Q2 2022 | -0.66% |
| Q1 2022 | -58.15% |
| Q4 2021 | 19.56% |
| Q3 2021 | -115.20% |
| Q2 2021 | 822.98% |
| Q1 2021 | -23.14% |
| Q4 2020 | -7.67% |
| Q3 2020 | -147.00% |
| Q2 2020 | 40.39% |
| Q1 2020 | -2375.83% |
| Q4 2019 | -98.15% |
| Q3 2019 | 439.66% |
| Q2 2019 | 14.00% |
| Q1 2019 | -52.64% |
| Q4 2018 | -42.18% |
| Q3 2018 | 19.73% |
| Q2 2018 | -10.73% |
| Q1 2018 | -54.47% |
| Q4 2017 | 20.23% |
| Q3 2017 | -9.00% |
| Q2 2017 | 35.18% |
| Q1 2017 | -35.90% |
| Q4 2016 | -42.50% |
| Q3 2016 | 5.91% |
| Q2 2016 | -42.99% |
| Q1 2016 | -114.96% |